TABLE 3.
Results of the statistical association tests from the discovery, replication, and meta-analysis phases with TG (P approaching borderline to genome-wide significance at >6.12E-09 and <5.0E-08) when modeled for the recessive and additive modes of inheritance
| SNP: Effect Allele | Gene: Functional Consequences | Phase | Effect Sizea | a | Effect Sizeb | b | Effect Sizec | c | Effect Sized | d |
| rs10873925: G#e | ST6GALNAC5: intron | Discovery | 0.633 | 4.11E-08 | 0.6031 | 4.19E-08 | 0.5899 | 6.15E-08 | 0.5669 | 2.32E-07 |
| Replication | 0.2035 | 0.0427 | 0.2092 | 0.03631 | 0.2182 | 0.0295 | 0.1874 | 0.059 | ||
| Meta | 5.364 | 8.12E-08 | 5.184 | 2.18E-07 | 5.418 | 6.03E-08 | 5.042 | 4.61E-07 | ||
| rs4663379: G#e | SPP2, ARL4C: intergenic | Discovery | 1.841 | 8.38E-09 | 1.842 | 8.39E-09 | 1.852 | 4.83E-09 | 1.79 | 1.73E-08 |
| Replication | 0.5718 | 0.005562 | 0.5861 | 0.0042 | 0.5585 | 0.0066 | 0.5514 | 0.00695 | ||
| Meta | 6.078 | 1.22E-09 | 6.051 | 1.44E-09 | 6.107 | 1.02E-09 | 5.938 | 2.89E-09 | ||
| rs10033119: G#e | NPY1R: 3′-utr | Discovery | 2.698 | 8.79E-09 | 2.695 | 9.24E-09 | 2.734 | 3.88E-09 | 2.745 | 3.69E-09 |
| Replication | 1.362 | 0.00064 | 1.336 | 0.00078 | 1.393 | 0.00046 | 1.257 | 0.0015 | ||
| Meta | 6.446 | 1.15E-10 | 6.583 | 4.60E-11 | 6.677 | 2.43E-11 | 6.455 | 1.08E-10 | ||
| rs17709449: T#e | LINC00911, FLRT2: intergenic | Discovery | 1.173 | 5.12E-08 | 1.172 | 5.36E-08 | 1.186 | 2.68E-08 | 1.141 | 9.64E-08 |
| Replication | 0.3883 | 0.02078 | 0.3937 | 0.0185 | 0.3797 | 0.02342 | 0.369 | 0.0265 | ||
| Meta | 5.447 | 5.12E-08 | 5.481 | 4.24E-08 | 5.585 | 2.34E-08 | 5.386 | 7.20E-08 | ||
| rs11654954: A#e | CDK12, NEUROD2: intergenic | Discovery | 0.9881 | 2.18E-08 | 0.9915 | 2.00E-08 | 0.9452 | 6.70E-08 | 0.9873 | 1.76E-08 |
| Replication | 0.3692 | 1.98E-02 | 0.3544 | 2.59E-02 | 0.3228 | 4.10E-02 | 0.3552 | 2.42E-02 | ||
| Meta | 5.602 | 2.13E-08 | 5.555 | 2.77E-08 | 5.261 | 1.43E-07 | 5.574 | 2.49E-08 | ||
| rs11654954: A@f | CDK12, NEUROD2: intergenic | Discovery | 0.3311 | 3.75E-08 | 0.3312 | 3.74E-08 | 0.3199 | 8.41E-08 | 0.3305 | 3.14E-08 |
| Replication | 0.1289 | 1.47E-02 | 0.1149 | 2.89E-02 | 0.1116 | 3.26E-02 | 0.1131 | 2.99E-02 | ||
| Meta | 5.612 | 2.00E-08 | 5.432 | 5.57E-08 | 5.298 | 1.17E-07 | 5.444 | 5.20E-08 | ||
| rs9972882: A#e | STARD3: intron | Discovery | 0.7284 | 1.81E-08 | 0.7287 | 1.80E-08 | 0.7137 | 2.56E-08 | 0.7208 | 2.00E-08 |
| Replication | 0.3311 | 4.43E-03 | 0.3168 | 5.73E-03 | 0.3043 | 7.83E-03 | 0.3205 | 5.01E-03 | ||
| Meta | 5.99 | 2.11E-09 | 5.918 | 3.25E-09 | 5.816 | 6.01E-09 | 5.949 | 2.70E-09 |
Effect size represents β value for discovery and replication phases and Z-score for meta-analysis.
Regular correction: corrected for age, sex, and the top 10 principal components that resulted from the PCA of the genotype data.
Corrected for lipid medication in addition to the regular correction.
Corrected for obesity (using BMI as the characterizing trait) in addition to the regular correction.
Corrected for diabetes status in addition to the regular correction.
Recessive model.
Additive model.